ALLENA PHARMACEUTICALS, INC. Inactive Instrument
Allena Pharmaceuticals, Inc.
Equities
ALNA
US0181191075
Biotechnology & Medical Research
Presenter SpeechMark Connolly (Analysts)Hi, everyone, and welcome to the 29th Annual Credit Su...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Allena Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Company is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company's lead product candidate, ALLN-346, is an orally administered, urate-degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The Company is conducting two Phase IIa for ALLN-346. The Company's wholly owned subsidiaries include Allena Pharmaceuticals Security Corporation (Security Corporation) and Allena Pharmaceuticals Ireland Limited.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.83% | 118B | |
| +10.14% | 106B | |
| -11.88% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.51% | 15.97B | |
| +6.40% | 14.03B | |
| +16.03% | 11.67B |
